Main Menu

Our therapeutic pipeline

The Institute of Cancer Research is the world’s leading academic centre for cancer drug discovery. Our scientists have discovered 21 new drug candidates since 2005, of which 13 have entered clinical trials, thanks to collaborations with our industry partners.

We also run one of the most successful academic drug development programmes in the world, in partnership with The Royal Marsden NHS Foundation Trust.

A graphical representation of cancer drugs from the ICR's therapeutic pipeline (full details listed further down the page)

More about our programmes

Each of the compounds to reach clinical trials has emerged from collaborative programmes involving multiple partners. The ICR is one of the world’s leading academic centres for industry collaboration and establishes long-term, fruitful and effective partnerships with industry. Find out more about each programme via the links below.

Abiraterone (CYP17)

The discovery and development of abiraterone (brand name Zytiga) is one of the ICR’s most famous successes and has benefitted many thousands of men with prostate cancer worldwide.

Find out more

Capivasertib (AKT)

Capivasertib was discovered following collaborative work between the ICR and partners and has entered phase III breast cancer trials.

Find out more

Pictilisib (PI3K)

Pictilisib has generated promising responses in several cancer types including breast and ovarian, myeloma, melanoma and a rare type of gastrointestinal cancer.

Find out more

Luminespib (Hsp90)

Previously called AUY922, the Hsp90 inhibitor luminespib was discovered by researchers at the ICR in collaboration with biotech company Vernalis.

Find out more

BTG945 (alpha-folate receptor)

This targeted treatment for ovarian cancer (also known as ONX-0901) has shown ‘very promising’ results in an early clinical trial. The ICR is seeking a partner to enable progression of this phase-II-ready compound and companion biomarker diagnostic test through to mid-late stage clinical development.

Read the brochure

NXP800 (HSF1 pathway)

NXP8000 is a highly innovative investigational drug discovered at the ICR. It has entered a phase I clinical trial sponsored by oncology-focused biopharmaceutical company Nuvectis Pharma.

Find out more

EP0042 (Aurora/Flt3)

EP0042 was discovered at the ICR and has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust. It is a dual inhibitor of cancer-driving proteins from the Aurora and FLT3 families – meaning it blocks the activity of both at once.

Find out more

BOS172722 (MPS-1)

BOS172722 blocks one of cancer’s key evolutionary escape routes from chemotherapy and could be used to treat aggressive breast cancers. The ICR and partners are seeking a partner for further clinical development.

Find out more

Fadraciclib (CYC065) (CDK2/9)

Fadraciclib, also known as CYC065, was jointly discovered by scientists at the ICR in collaboration with the company Cyclacel.

Find out more

SRA737 (CHK1)

SRA737 was discovered and initially developed by scientists at the ICR, in collaboration with the company Sareum Holdings plc and with funding from Cancer Research UK.

Find out more

BAL3833 (panRAF)

BAL3833 is an experimental skin cancer drug that has entered a phase I clinical trial.

Find out more


CHR-3996 was discovered in a collaboration between the ICR and Chroma Therapeutics.

Find out more

Undisclosed compound (GSPT1)

Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at the ICR, is focused on discovering and developing molecular glues. Its lead drug programme comes from research geared towards targeting a protein called GSPT1, which was originally initiated by researchers at the ICR.

Find out more